AI-driven platform accelerates drug discovery workflows

Sapio Sciences has integrated the NVIDIA BioNeMo platform into its lab informatics platform, enhancing AI-driven computational drug discovery. By embedding BioNeMo within Sapio ELN (Electronic Lab Notebook), researchers can streamline workflows, optimise molecular modelling, and improve decision-making in early-stage drug development.

The integration provides access to powerful AI tools, including AlphaFold2 NIM for protein structure prediction, MoIMIM NIM for small molecule design, and DiffDock NIM for AI-powered molecular docking. These capabilities enable scientists to generate novel candidate molecules, predict protein-ligand interactions, and refine drug targets with greater efficiency.

Kevin Cramer, Founder, CEO & CTO at Sapio Sciences, emphasised the significance of the collaboration: “Researchers often face challenges with fragmented AI tools that slow down innovation. By integrating NVIDIA’s cutting-edge AI models directly into Sapio ELN, we are providing scientists with seamless access to advanced drug discovery capabilities, eliminating inefficiencies and accelerating research.”

Anthony Costa, Director of Digital Biology at NVIDIA, added: “AI is reshaping pharmaceutical research, and this integration ensures that scientists can harness generative AI for faster, more accurate drug development. With BioNeMo's molecular modelling capabilities now embedded in Sapio’s platform, researchers can optimise drug candidates with unprecedented speed.”

This integration underscores Sapio Sciences’ commitment to advancing biopharmaceutical innovation by leveraging AI to drive data-driven research and accelerate the transition from discovery to development.

More information online